Compare Charles River Laboratories Intl. Inc (CRL) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs T Rowe Price Group Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $303.31 (market cap $14.23B), while T Rowe Price Group Inc trades at $105.06 (market cap $22.23B). The key difference: T Rowe Price Group Inc is the larger of the two by market cap, and T Rowe Price Group Inc pays a 4.99% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and T Rowe Price Group Inc for 115 Days on average.
| CRL | TROW | |
|---|---|---|
Market Cap | $14.23B | $22.23B |
Volume | 1,176,885 | 2,834,949 |
Sector | Health | Financials |
52-Week High | $310.77 | $121.68 |
52-Week Low | $149.93 | $86.19 |
Typical Hold Time | 33 Days | 115 Days |
Enterprise Value | $17.06B | $19.43B |
Dividend Yield | — | 4.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
T. Rowe Price (TROW) trades at $105.47, up 1.35% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with a P/E of 10.46, net income margin of 29.26%, and consistent dividend growth spanning 40 years. Recent earnings beat expectations in Q1 and Q2 2026, while AUM reached $1.90 trillion in August 2026 despite net outflows.
The stock presents value characteristics with attractive valuation multiples and dividend yield near 5%, though technical weakness and analyst caution (63% hold rating) suggest near-term consolidation. Key catalysts include Q3 earnings due soon and the company's expansion into ETF offerings through F/m Investments acquisition, while risks include market-sensitive revenue and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
